Stand Up To Cancer Teams Up with Johnson & Johnson
Stand Up To Cancer (SU2C) has recently announced an important collaboration with Johnson & Johnson aimed at advancing the research of targeted therapies. This partnership focuses on the testing of two specific therapies: teclistamab and daratumumab. These treatments are being investigated for their potential efficacy against AL amyloidosis, a rare disease impacting around 4,500 individuals in the U.S. each year. This condition has associations with various blood cancers, including multiple myeloma, lymphomas, and chronic lymphocytic leukemia.
The Importance of Continued Research
Jessica Vermeulen, the vice president at Johnson & Johnson for Oncology Late Development, emphasizes the need for ongoing research despite the advent of new treatment options. "Our team is thrilled to partner with Stand Up To Cancer in this new research initiative, which holds great promise for oncology, particularly due to the similarities in treatment strategies between AL amyloidosis and blood cancers like multiple myeloma," said Vermeulen.
Understanding AL Amyloidosis
AL amyloidosis occurs when abnormal plasma cells accumulate an excess of a particular protein known as amyloid in organs and tissues. The body struggles to eliminate this amyloid buildup, adversely affecting vital organs, including the heart, kidneys, liver, and nerves. While primarily impacting men and those aged over 50, younger individuals can also be diagnosed with this condition. Interestingly, about 15% of patients suffering from multiple myeloma are simultaneously affected by AL amyloidosis.
The Role of Targeted Therapies
Both teclistamab and daratumumab play significant roles in targeting cancerous cells. Teclistamab acts by linking abnormal plasma cells with immune system T cells, thereby triggering T cell activity to destroy the abnormal cells. On the other hand, daratumumab directly targets a specific protein on plasma cells, which helps eliminate these cells while signaling the immune system for additional assistance. By combining these two treatments, researchers hypothesize a more robust attack on multiple proteins associated with the disease, possibly enhancing the overall efficacy against AL amyloidosis.
Research Applications and Future Steps
U.S. researchers interested in exploring these new therapeutic avenues are encouraged to apply before the application deadline. The award notifications are expected in the following months, with project initiations planned for later. This research is primarily supported through a SU2C Catalyst grant, a unique grant mechanism aimed at quickly generating preliminary efficacy and safety data to drive further research development.
About Stand Up To Cancer
Stand Up To Cancer was established to support cancer research and raise awareness, with the vision of improving cancer treatment outcomes. Since its inception in 2008, it has rallied over 3,100 scientists from more than 210 research institutions. Through collaborative efforts, SU2C aims to foster a fresh model of cancer research that heightens awareness and accelerates scientific achievements in the battle against cancer.
About Johnson & Johnson
Johnson & Johnson champions health as a core pillar of its operations. The company is dedicated to healthcare innovation, aiming to produce smarter, less invasive medical solutions that cater to personal health needs. They leverage their extensive expertise in innovative medicine to create impactful health solutions for tomorrow.
Frequently Asked Questions
What is the purpose of the collaboration between SU2C and Johnson & Johnson?
The collaboration aims to explore and support research on targeted therapies intended to treat AL amyloidosis, a rare disease related to certain blood cancers.
What are teclistamab and daratumumab?
Teclistamab and daratumumab are targeted therapies that focus on treating abnormal plasma cells, with the goal of improving outcomes for patients with diseases like AL amyloidosis.
Who does AL amyloidosis primarily affect?
AL amyloidosis predominantly impacts older adults, particularly men, although it can occur in younger individuals. It's often associated with blood cancers like multiple myeloma.
How can researchers get involved in this study?
U.S. investigators interested in this research can submit applications through the specified platform by the deadline for consideration.
What is the significance of the SU2C Catalyst grant?
The SU2C Catalyst grant is designed to swiftly yield early efficacy and safety data to bolster development efforts, particularly for treatments targeting diseases like AL amyloidosis.
